Raymond James reissued their buy rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note published on Monday morning, AnalystRatings.com reports.
Several other brokerages also recently commented on TEVA. SVB Leerink raised their target price on shares of Teva Pharmaceutical Industries from $13.00 to $14.00 and gave the stock a market perform rating in a report on Thursday, August 6th. SunTrust Banks upgraded shares of Teva Pharmaceutical Industries from a hold rating to a buy rating and lifted their price objective for the company from $11.00 to $16.00 in a report on Monday, June 1st. Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a report on Monday, July 27th. They issued a neutral rating and a $12.00 price objective on the stock. Bank of America reiterated a sell rating and issued a $8.00 price objective on shares of Teva Pharmaceutical Industries in a report on Wednesday, August 26th. Finally, Barclays upgraded shares of Teva Pharmaceutical Industries from an underweight rating to an equal weight rating and lifted their price objective for the company from $10.00 to $13.00 in a report on Thursday, August 6th. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $12.40.
Teva Pharmaceutical Industries stock opened at $9.19 on Monday. The company’s 50 day simple moving average is $10.41 and its 200 day simple moving average is $10.75. Teva Pharmaceutical Industries has a fifty-two week low of $6.25 and a fifty-two week high of $13.76. The firm has a market capitalization of $10.04 billion, a price-to-earnings ratio of 3.98, a PEG ratio of 0.67 and a beta of 1.50. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.09 and a quick ratio of 0.72.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.94 billion. Teva Pharmaceutical Industries had a net margin of 0.03% and a return on equity of 17.88%. Teva Pharmaceutical Industries’s quarterly revenue was down 7.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.60 EPS. As a group, analysts predict that Teva Pharmaceutical Industries will post 2.39 EPS for the current fiscal year.
In other Teva Pharmaceutical Industries news, Director Rosemary A. Crane sold 2,860 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $11.90, for a total value of $34,034.00. Following the completion of the sale, the director now owns 36,369 shares in the company, valued at $432,791.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.56% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. CIBC Asset Management Inc boosted its stake in shares of Teva Pharmaceutical Industries by 6.0% during the second quarter. CIBC Asset Management Inc now owns 83,716 shares of the company’s stock worth $1,032,000 after buying an additional 4,754 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Teva Pharmaceutical Industries in the 1st quarter worth approximately $175,000. Cambridge Investment Research Advisors Inc. lifted its position in Teva Pharmaceutical Industries by 91.5% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 304,822 shares of the company’s stock worth $2,737,000 after buying an additional 145,683 shares during the last quarter. SG Americas Securities LLC lifted its position in Teva Pharmaceutical Industries by 177.6% in the 2nd quarter. SG Americas Securities LLC now owns 387,239 shares of the company’s stock worth $4,775,000 after buying an additional 247,750 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $297,000. Institutional investors and hedge funds own 52.87% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: Gross Domestic Product (GDP)
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.